Can you get a GLP-1 through telehealth in your state?

The short answer: yes, a GLP-1 such as semaglutide or tirzepatide can be prescribed by telehealth in every state, because they are not controlled substances. What changes from state to state is how the visit must happen, who may prescribe, and which pharmacies may ship to you. Those differences decide whether a given program is lawful where you live.

This guide covers access only. Dosing belongs with your prescriber and the product label. If you are still choosing between the two drugs, semaglutide vs tirzepatide sets their trial results side by side.

What does federal law require for a telehealth GLP-1?

The strictest federal telehealth rule is for controlled substances: the Ryan Haight provisions generally require an in-person evaluation before a controlled substance is prescribed online. [1] GLP-1 drugs are not controlled substances, so that rule does not apply to them. Everything else is set by the state where you are physically located when you are treated. Our federal guide summarizes the national rules.

That leaves three state-level questions:

1. The visit. Does the state accept an asynchronous visit (forms, photos, records reviewed later), or does it expect live video?
2. The prescriber. Must the clinician hold a license in your state, or can they register from elsewhere?
3. The pharmacy. Is the dispensing pharmacy licensed or registered to ship into your state?

How do state telehealth rules differ?

These five examples show how much the answers vary. Each links to our full state guide.

Texas: defined methods. Texas law lists the ways a valid practitioner-patient relationship can exist for a telemedicine service. Beyond a preexisting relationship or call coverage, the practitioner can use synchronous audiovisual interaction; asynchronous store-and-forward technology, provided it uses clinically relevant images or the patient's relevant clinical records; or another audiovisual technology that meets the standard of care. [2] An asynchronous GLP-1 visit in Texas therefore needs real clinical information behind it. When the relationship starts by telemedicine, the practitioner must also give follow-up guidance and, if you consent, notify your primary care physician. [2] See the Texas guide.

California: questionnaires can qualify. California makes it unprofessional conduct to prescribe without an appropriate prior examination, but the statute says that exam does not require a synchronous interaction and can be done through telehealth, including a self-screening tool or questionnaire, as long as the standard of care is met. [3] Before telehealth care starts, the provider must get and document your verbal or written consent to it. [11] See the California guide.

Florida: registration for out-of-state clinicians. Florida defines telehealth to include synchronous and asynchronous technology and excludes email and fax. A telehealth provider does not need to research the patient's history or do a physical exam first if the telehealth evaluation is sufficient to diagnose and treat. Clinicians licensed elsewhere can register with the state to provide telehealth to Florida patients if they meet the statute's conditions, but that registration does not let them open a Florida office or see patients in person. [4] See the Florida guide.

Arizona: registration with conditions. Arizona also lets out-of-state providers serve Arizona patients by telehealth after registering with the relevant Arizona board. The provider must hold an unrestricted license elsewhere, carry liability insurance, and follow Arizona's prescribing and telehealth rules. [6] Telehealth care in Arizona is held to the same standard of care as an in-person visit. [12] See the Arizona guide.

New York: a narrow store-and-forward definition. New York defines store-and-forward technology as the asynchronous transmission of patient-specific digital images or pre-recorded videos. [7] That definition covers images and videos and does not mention questionnaires. See the New York guide.

The other states are in our state legal guides, each with its board of pharmacy, telehealth statute, and sources.

Which states require a live visit for a first GLP-1 prescription?

Some states rule out the questionnaire-only model that many online weight-loss programs use, so a program that is lawful in California can be unlawful one state away.

Georgia is the strictest example. A Georgia Composite Medical Board rule makes it unprofessional conduct to treat by electronic means unless a Georgia licensee has done a history and physical examination, with narrow exceptions for coverage and consultation. [13] The Board's telemedicine rule otherwise requires that the patient was examined in person, was referred by a Georgia clinician who examined them, or is examined with technology equal or superior to an in-person exam. [14] Georgia law defines a dangerous drug as any drug that federal law limits to prescription, which covers GLP-1s. [15] See the Georgia guide.

West Virginia allows telemedicine, but a first encounter must use real-time video or a real-time call, and the statute says a prescription based solely on an online questionnaire does not meet the standard of care. [16] See the West Virginia guide.

New Jersey requires telemedicine to use interactive, real-time, two-way communication. Store-and-forward technology can carry images and records, but it does not replace the live interaction. [17] See the New Jersey guide.

Arkansas does not let a professional relationship be established only by an internet questionnaire, email, patient-generated history, text messages, fax, or any mix of them. [18] See the Arkansas guide.

Louisiana changed its rules for weight care in 2026. Act 345 bars the state's medical and nursing boards from enforcing any rule that prohibits telehealth treatment of obesity, as long as the provider has a synchronous interaction with the patient and follows the standard of care. [19] Telehealth weight management is allowed there, but not through a form alone. See the Louisiana guide.

What does the pharmacy need to ship a GLP-1 to you?

For branded GLP-1s, the prescription usually goes to a retail pharmacy or a manufacturer's direct-to-patient pharmacy. For compounded product, the pharmacy question is sharper.

FDA's shortage-based allowances for compounded tirzepatide and semaglutide ended in 2025: the last 503A deadlines were February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide. [8] A compounded GLP-1 now needs a documented patient-specific reason. The pharmacy also has to be allowed to ship into your state, and each state names that permission differently:

• Florida: an out-of-state pharmacy that ships to Florida patients registers as a nonresident pharmacy, [20] and one that ships compounded sterile products, which covers injectables, also needs a nonresident sterile compounding permit. [5]
• Texas: pharmacies are licensed by the Texas State Board of Pharmacy, [22] and one that compounds sterile preparations must meet the Board's sterile compounding rule. [21]
• California: a nonresident pharmacy that ships sterile compounded products into the state needs a nonresident sterile compounding license. [23]
• Arizona: a pharmacy outside the state may not ship prescription drugs into Arizona without a nonresident permit from the Arizona board. [24]
• New York: every out-of-state pharmacy or outsourcing facility that ships prescription drugs to New York patients must register with the state as a nonresident establishment. [25]

Check that the pharmacy appears in your state board's license lookup before the first shipment.

Does your state limit compounded GLP-1s beyond federal law?

Most states follow the federal 503A rules for what may be compounded. California goes further on copies. Its compounding regulations treat a compounded drug as essentially a copy of a commercial product unless a change for an identified patient makes a clinically significant difference that the pharmacist verifies and documents, and a different strength or route alone does not count. [26] In practice, a lower price is not a reason to compound semaglutide or tirzepatide for a California patient. Our cost pages show what the branded routes cost instead.

What are the red flags in telehealth GLP-1 programs?

On March 3, 2026, FDA announced warning letters to 30 telehealth companies over how they marketed compounded GLP-1 drugs. The problems included implying compounded products were the same as FDA-approved drugs, calling them generics, and selling them under the telehealth firm's own brand in a way that suggested the firm made them. [9] Walk away from any program that:

• Prescribes after a form with no clinical review, in a state that requires more.
• Will not tell you the prescriber's name and state license.
• Will not name the dispensing pharmacy or show its license for your state.
• Calls a compounded product "generic" or "the same as" a branded drug.

Does telehealth change what insurance covers?

No. Telehealth does not change what your insurance covers. One recent change applies to Medicare: from July 1, 2026, eligible Part D enrollees can get Wegovy (injection or tablets) or the Zepbound KwikPen for a 50 USD monthly copay under the Medicare GLP-1 Bridge. The prescriber must send the prescription and complete prior authorization when requested. [10] Current cash prices are on the tirzepatide cost page and semaglutide cost page.

What should you check before you sign up?

• Confirm the prescriber is licensed in, or registered with, your state.
• Ask what kind of visit your state requires, and whether the program meets it.
• Get the dispensing pharmacy's name and verify its license for your state.
• If compounded product is offered, ask for the documented clinical reason.

For the whole drug class, including approval status and prices side by side, see the GLP-1 hub.